Cargando…
XPF–ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer
5-FU-based chemoradiotherapy (CRT) and oxaliplatin-based CRT are commonly used therapies for advanced colorectal cancer (CRC). However, patients with a high expression of ERCC1 have a worse prognosis than those with a low expression. In this study, we investigated the effect of XPF–ERCC1 blockers on...
Autores principales: | Huang, Ming-Yii, Huang, Yi-Jung, Cheng, Tian-Lu, Jhang, Wun-Ya, Ke, Chien-Chih, Chen, Yi-Ting, Kuo, Shih-Hsun, Lin, I-Ling, Huang, Yu-Hsiang, Chuang, Chih-Hung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252687/ https://www.ncbi.nlm.nih.gov/pubmed/37296596 http://dx.doi.org/10.3390/cells12111475 |
Ejemplares similares
-
HIF-1α Expression Increases Preoperative Concurrent Chemoradiotherapy Resistance in Hyperglycemic Rectal Cancer
por: Huang, Yi-Jung, et al.
Publicado: (2022) -
ERCC1 Overexpression Increases Radioresistance in Colorectal Cancer Cells
por: Huang, Yi-Jung, et al.
Publicado: (2022) -
Acetylation of XPF by TIP60 facilitates XPF-ERCC1 complex assembly and activation
por: Wang, Jiajia, et al.
Publicado: (2020) -
Association of ERCC1 and XPF polymorphisms with pediatric glioma susceptibility
por: Chen, Yongping, et al.
Publicado: (2023) -
Expression and Clinical Significance of ERCC1 and XPF in Human Hepatocellular Carcinoma
por: Liao, Xiaoli, et al.
Publicado: (2020)